Complement C4 is Reduced in iPSC-Derived Astrocytes of Autism Spectrum Disorder Subjects

Fernanda Mansur  
Hospital Israelita Albert Einstein

André Luiz Teles e Silva  
Hospital Israelita Albert Einstein

Ana Karolyne Santos-Gomes  
Hospital Israelita Albert Einstein

Juliana Magdalon  
Hospital Israelita Albert Einstein

Janaina Sena de Souza  
Universidade Federal de Sao Paulo

Karina Griesi-Oliveira  
Hospital Israelita Albert Einstein

Maria Rita Passos-Bueno  
Universidade de Sao Paulo

Andrea Laurato Sertie (✉️ andre.a.sertie@einstein.br)  
Hospital Israelita Albert Einstein  https://orcid.org/0000-0002-7453-0560

Research Article

Keywords: Complement system, autism spectrum disorder, iPSC-derived astrocytes, complement C4, synaptic pruning

DOI: https://doi.org/10.21203/rs.3.rs-297808/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

In recent years, accumulating evidence has shown that the innate immune complement system is involved in several aspects of normal brain development and in neurodevelopmental disorders, including autism spectrum disorder (ASD). Although abnormal expression of complement components was observed in post-mortem brain samples from individuals with ASD, little is known about the expression patterns of complement molecules in distinct cell types in the developing autistic brain. In the present study, we characterized the mRNA and protein expression profiles of a wide range of complement system components, receptors and regulators in induced pluripotent stem cell (iPSC)-derived neural progenitor cells, neurons and astrocytes of individuals with ASD and neurotypical controls, which constitute in vitro cellular models that recapitulate certain features of both the human brain development and ASD pathophysiology. We observed that all the analyzed cell lines constitutively express several key complement molecules. Interestingly, using different quantification strategies, we found that complement C4 mRNA and protein are expressed in significantly lower levels by astrocytes derived from ASD individuals compared to control. As astrocytes participate in synapse elimination and diminished C4 levels have been linked to defective synaptic pruning, our findings may contribute to an increased understanding of the atypically enhanced brain connectivity in ASD.

Introduction

The complement system, which plays crucial roles in the innate defense against pathogens and damaged cells [1], has been increasingly implicated in brain development and plasticity [2, 3]. All major cell types in the brain were shown to constitutively express at least some components, receptors and regulators of the three pathways of complement activation - classical, lectin and alternative -, which contribute to some key cellular processes in the developing brain, including neurogenesis [4], neuronal migration [5], and synapse pruning and remodeling [6–9]. Consequently, inappropriate expression or activation of the complement system might alter the establishment of precise neural networks in the brain during development, resulting in cognitive dysfunction. Indeed, a growing number of studies has associated dysregulation of specific components of the complement system with neurodevelopmental disorders [10], such as schizophrenia [8] and autism spectrum disorder (ASD) [11, 12].

ASD is a heterogeneous neurodevelopmental condition characterized by deficits in social interaction and the presence of repetitive, restricted behaviors [13]. The etiology of ASD is very complex and may involve genetic, epigenetic, environmental and immunological risk factors [14, 15]. Previous studies have found a potential association between abnormal expression of complement system elements and ASD risk. Genetic variants in the complement C4B gene resulting in non-expression of the gene (C4B null alleles) were associated with increased risk for this disorder [16–18]. Altered levels of complement proteins - such as C4, C1q, C3, C5 and CFI - were observed in the periphery of individuals with ASD [19–22]. Finally, the expression patterns of several complement genes - such as C1q, C2, C3, C4, MASP1 and CR3 - were found to differ in post-mortem brain tissue samples from ASD subjects compared to control subjects [11, 12].
However, the expression profile of complement genes and proteins during the initial stages of human neurodevelopment and the specific cell types in the brain from ASD individuals that differentially express complement components are still largely unexplored. Human induced pluripotent stem cell (iPSC)-derived brain cells have been successfully used to model ASD (23–26), and a recent study from our group has shown that the transcriptome profiles from iPSC-derived neural progenitor cells (NPCs) and neurons best reflects neuronal tissue at early (4–10 post-conception weeks) and middle (16–24 post-conception weeks) stages of prenatal brain development respectively [27]. This study aimed to characterize the constitutive mRNA and protein expression levels of a wide range of complement system components, receptors and regulators in neuronal (NPCs and neurons) and glial (astrocytes) cells derived from iPSCs of individuals with ASD and neurotypical controls, and to identify possible differences in complement expression between the ASD and control cells.

**Material And Methods**

**Subjects and genetic analysis**

All individuals evaluated in this study (n = 7 individuals with non-syndromic ASD and n = 5 neurotypical controls) were described previously [27–30]. CGH-array and whole exome sequencing using genomic DNA from peripheral blood of the ASD subjects and their parents allowed the identification of known ASD pathogenic variants in two individuals: one patient harbors deleterious compound heterozygous variants in the RELN gene, and a *de novo* splice site variant in the CACNA1H gene; the second patient harbors a duplication of 15q11-13. The remaining five patients did not harbor rare variants that cause a known deleterious loss of function of an ASD gene.

**Human iPSCs generation and differentiation into neural progenitor cells**

All iPSC samples used in this study have been previously generated and characterized [27, 29]. For iPSC differentiation into NPCs, iPSCs were suspended to generate embryoid bodies and plated to produce neural rosettes, which were manually isolated, dissociated, and cultured on dishes coated with 10 µg/ml poly-L-ornithine and 5 µg/ml laminin in NPC medium containing: DMEM/F12, 0.25x N2-supplement (Thermo Fischer Scientific), 0.5x B27-supplement (Thermo Fischer Scientific), 20 ng/ml of FGF and 20 ng/ml EGF (Peprotech, NJ, USA). Cell culture medium was changed every other day. NPCs derived from either 1 or 2 iPSC clones of each subject were used in all experiments described herein.

**Differentiation of neural progenitor cells into neurons**

Neurons were obtained after 4 weeks of differentiation from NPCs as previously described [27]. Briefly, NPCs were seeded on plates coated with 20 µg/ml poly-L-ornithine and 10 µg/ml laminin. After reaching 50% confluence, cells were cultured with DMEM/F12 medium supplemented with 0.5x N2, 1x B27, and 1 µM of retinoic acid (Sigma-Aldrich), which was changed every three days. Neurons derived from either 1 or 2 iPSC clones of each subject were used in all experiments described herein.
Differentiation of neural progenitor cells into astrocytes

Astrocytes were differentiated from NPCs as previously described [31]. Briefly, NPCs were mechanically detached and cultured in suspension in ultra-low attachment plates with NPC medium under agitation at 90 rpm to allow for 3D sphere formation. Twenty-four hours later, the medium was changed to DMEM/F12 supplemented with 0.5x N2, 0.5x B27 and 10 µM ROCK inhibitor, and spheres were maintained in suspension culture for 48 hours. Subsequently, the medium was changed to Astrocyte Growth Medium (AGM Bullet Kit, Lonza), and spheres were maintained in suspension culture for additional 15 days. Cell culture medium was changed every other day. The spheres were then seeded on plates coated with 10 µg/ml poly-L-ornithine and 5 µg/ml laminin and cultured in AGM until astrocytes spread from adherent spheres. When astrocytes reached confluency, spheres were manually removed and astrocytes were passaged at least three times before usage in any experiment. Astrocytes derived from either 1 or 2 iPSC clones of each subject were used in all experiments described herein.

Immunofluorescence

Each cell line was seeded on cover slips coated with poly-L-ornithine and laminin. Cell monolayers were fixed with 4% paraformaldehyde (Sigma Aldrich) and, after permeabilization with blocking buffer (5% donkey serum and 1% triton in PBS) at room temperature for 1 hour, cells were incubated with the following primary antibodies diluted in blocking buffer overnight at 4°C: anti-SOX2 (1:100, AB5603; Millipore); anti-Nestin (1:250, MAB5326; Millipore), anti-βIII-tubulin (1:2,000, MMS435P; Covance), anti-MAP2 (1:500, M9942; Sigma-Aldrich), anti-GFAP (1:1,000, AB5804; Millipore), anti-CD44 (5µg/ml, ab6124; Abcam). Subsequently, cells were washed with PBS and incubated at room temperature for 1 hour with secondary antibodies conjugated with AlexaFluor594 or AlexaFluor488 (1:400; Thermo Fisher Scientific). Nuclei were stained with DAPI (VECTASHIELD, Vector Laboratories). Fluorescence images were obtained using a Zeiss LSM 710 confocal microscope system.

Protein extraction and immunoblotting

Total protein extracts from each cell line were obtained using Ripa Buffer containing protease and phosphatase inhibitor cocktails (Sigma Aldrich) and quantified using BCA assay (Thermo Fisher Scientific). For immunoblotting, total proteins (20 µg) were separated by SDS– PAGE and transferred to nitrocellulose membranes (GE HealthCare), which were then blocked and incubated overnight at 4°C with the following primary antibodies: anti-SOX2 (1:1,000, AB5603; Millipore), anti-Nestin (1:1000, MAB5326; Millipore), anti-βIII-tubulin (1:2,000, MMS435P; Covance), anti-GFAP (1:1,000, AB5804; Millipore), anti-CD44 (1:1000, ab6124; Abcam), and anti-β-actin (1:10,000, A2228; Sigma Aldrich) for loading control. In addition, the following antibodies were used against C3aR1 and C5aR1 proteins and produced multiple nonspecific bands on western blots using total protein from NPC, neuron and astrocyte lysates: ab126250 and ab59390 (Abcam) respectively. Detection was performed using horseradish peroxidase–coupled anti-rabbit or anti-mouse secondary antibodies (1:2,000, #7074 or #7072; Cell Signaling Technology), ECL substrate (Bio-Rad), and the ChemiDoc MP Imaging System (Bio-Rad). The intensity of
the bands was determined by densitometry using The Image Lab Software (Bio-Rad). The graphs show
the relative expression levels for each group (Control and ASD) with mean and SD and combine results
from two independent experiments.

RNA extraction and quantitative real-time PCR

Total RNA from each cell line was extracted using the NucleoSpin® RNA kit (Macherey-Nagel) following
the manufacturer’s instructions. RNA quality and quantity were assessed using the NanoDrop 3300
Fluorospectrometer (Thermo Fisher Scientific). The cDNA was synthesized from 500 ng of total RNA with
SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific). The qPCR reactions were
performed with 60 ng of cDNA and predesigned TaqMan gene expression assays in a QuantStudio 6 Flex
Real-Time PCR System (Applied Biosystem). The expression levels of 20 target genes of the complement
system (C1R, C1S, C2, C3, C4A/B, C5, C7, MBL2, MASP1, MASP2, CFB, CFD, C3aR1, C5aR1, SERPING1,
CFH, CFI, and CD59) were normalized to the mean expression value of the GAPDH and HMBS
housekeeping genes. It is noteworthy that the qPCR assay used detects the highly homologous C4A and
C4B genes. Results are expressed as the mean fold change of the normalized gene expression relative to
a calibrator sample using the comparative CT method (2−ΔΔCt method). The dot-plots show the transcript
levels for each individual in the Control and ASD groups and combine results from two independent
experiments.

Multiplex and ELISA assays

Cells were cultured until 90% confluence in 60 mm tissue culture plates, and the supernatants were
collected after 48h cultures and centrifuged to remove cell debris. Cell-free supernatants (2.5 mL) were
then transferred to a new conical tube, and the proteins in the supernatants were precipitated by adding
ice-cold acetone (4:1) and resuspended in 250 ul of RIPA buffer containing protease inhibitors (10x
concentrated supernatants). The concentration of 13 complement components and regulators were
quantified in cell culture supernatants by using the Luminex xMAP detection system and the Human
Complement Panel 1 and 2 Bead-Based Multiplex Assay kits (HCMP1MAG-19K and HCMP2MAG-19K,
Millipore), whose detection sensitivities are (minimum detectable concentrations): C2 = 310 pg/ml, C4b =
360 pg/ml, C5 = 1040 pg/ml, C5a = 5.1 pg/ml, CFD = 26pg/ml, MBL = 40 pg/ml, CFI = 220 pg/ml, and C1q
= 48 pg/ml, C3 = 120 pg/ml, C3b/iC3b = 3639 pg/ml, C4 = 191 pg/ml, CFB = 24 pg/ml, CFH = 135 pg/ml
respectively. Data acquisition and analysis were performed using the Luminex® xPONENT® and the
Milliplex® Analyst 5.1 softwares (Millipore), respectively. Values below the minimum detectable
concentrations of the multiplex assays were not considered. C4 protein levels were also quantified in
astrocyte culture supernatants in a full set of independent experiments (including novel astrocyte
differentiation, protein extraction and quantification) by using an ELISA assay (Human Complement C4
ELISA kit, ab108825, Abcam) following manufacturer's instructions. Optical densities measurements
were taken at 450 nm using a GloMax® Discove Microplate Reader (Promega). All test samples fell
above the minimum detectable concentration of the ELISA assay (41 pg/ml). Results were normalized to
the total protein content of the cell lysates and were expressed in pg/ml. The dot-plots show the protein
levels for each individual in the Control and ASD groups and combine results from two independent experiments.

**Statistical analysis**

Statistical analyses were carried out using the generalized linear mixed-effect model in SPSS software to account for dependency between biological replicates (when NPCs, neurons and astrocytes derived from different iPSC clones of the same individual were used) and independent technical replicates per individual. P values < 0.05 were considered statistically significant. Data obtained by RT-qPCR, multiplex and ELISA analysis were represented as median with interquartile range.

**Results**

Generation of iPSC-derived neural progenitor cells, neurons and astrocytes from ASD and control subjects

iPSCs from individuals with ASD (n = 7) and control subjects (n = 5) were differentiated into NPCs, post-mitotic neurons and astrocytes, and the expression of lineage-specific markers was confirmed by immunocytochemistry and western blotting. We did not detect any major differences between ASD and control cells with respect to the differentiation capacities and no significant differences in the expression levels of the lineage markers were observed between the two groups (Fig. 1). To examine the constitutive expression profiles of complement system in these human neuronal and glial cell types, we combined mRNA and protein quantification assays.

**Expression of complement genes in iPSC-derived neural progenitor cells, neurons and astrocytes**

First, we examined the gene expression levels of several complement system components (C1R, C1S, C2, C3, C4A/B, C5, C7, C9, MBL2, MASP1, MASP2, CFB, CFD), receptors (C3aR1 and C5aR1), and regulators (SERPING1, CFH, CFI, and CD59) in control- and ASD-derived NPCs, neurons and astrocytes by RT-qPCR. The results showed that, except for MBL2, mRNA transcripts for these key complement genes are detected in all cell samples analyzed. Some genes exhibit highly variable expression across samples, and the expression values of most genes are significantly higher in neurons than in NPCs and astrocytes (Fig. 2a-c). No significant differences in mRNA expression levels were found between control and ASD NPCs, as well as between control and ASD neurons. On the other hand, a significant decrease in the expression levels of C4A/B (paralogous C4A and C4B genes) was observed in astrocytes derived from ASD subjects compared to control astrocytes (p = 0.009) (Fig. 2c).

**Expression of complement proteins in iPSC-derived neural progenitor cells, neurons and astrocytes**

Next, protein levels of several soluble complement components (C1q, C2, C3, C3b/iC3b, C4, C4b, MBL, C5, C5a, CFB, CFD) and regulators (CFH and CFI) in culture supernatants from control- and ASD-derived
NPCs, neurons and astrocytes were measured by multiplex assays. The results indicated that all cell samples secrete reliably detectable amounts (above the lower limit of detection of the multiplex assays) of C4, C5a, CFB, CFH and CFI, and that the expression levels of most of these proteins vary substantially across samples. Notably, neurons and astrocytes secreted significantly higher levels of C4 than NPCs, and detectable levels of C4b, a C4 cleavage product, were only observed in the supernatants of these cell types. Also, astrocytes and neurons also secrete reliably detectable levels of CFD (Fig. 3a-c). Protein levels of C1q, C2, C3, C3b/iC3b, C5, and MBL were below the lower limit of detection of the multiplex assays in culture supernatants from most samples and were not considered for further analysis (data not shown).

Interestingly, whereas no significant differences in the secretion levels of complement proteins were found between control and ASD neuronal and glial cells, we observed a strong tendency towards decreased secretion of C4 and C4b by ASD astrocytes compared to control astrocytes (Fig. 3c), which is in accordance with the significant diminished C4A/B mRNA expression in these cells. In order to confirm the obtained results, the C4 protein level was also quantified in astrocyte culture supernatants by using a human C4 ELISA assay and a full set of independent experiments (with a larger sample of astrocytes). The results revealed that ASD astrocytes under steady-state conditions indeed secrete significantly lower levels of C4 compared to control astrocytes (p = 0.001) (Fig. 3d).

Discussion

In this study, we investigated the production of the main components of the three complement pathways and their key receptors and regulators in human iPSC-derived NPCs, neurons and astrocytes of ASD and control subjects, which are in vitro models that recapitulate some molecular and cellular aspects of the developing human brain.

We observed that although a large number of complement genes are transcribed in human NPCs, neurons, and astrocytes, these cells under normal conditions may be an effective local source of only a specific set of complement components and regulators. We found that all analyzed cell samples express mRNA transcripts for C5 and C5a receptor (C5aR1), and secrete similar levels of the C5a protein, produced from cleavage of C5. Studies using mouse models have shown that absence of C5a-C5aR1 signaling results in neural tube defects in folate-deficient mouse embryos [32], and that pharmacological blockade of C5aR1 during neurogenesis inhibits NPC proliferation in the ventricular zone of mouse embryos and leads to behavioral abnormalities later in life [4]. Interestingly, in vitro studies have shown that C5a and C5aR1 are constitutively expressed in human embryonic stem cells and iPSCs regulating their pluripotency [33], in human NPCs promoting polarization and proliferation of these cells [34], in human fetal astrocytes regulating calcium transient activity [35], and also in mouse cortical neurons inducing apoptosis [36, 37]. Although we did not observe any differences in the expression patterns of C5a and C5aR1 between ASD and control neuronal and glial cells, our results corroborate the findings of previous studies showing expression and physiological roles of these complement molecules in different cell types in the developing human brain.
We also found that all analyzed ASD and control cell lines express CFB mRNA and secrete relatively low levels of CFB protein, an activator of the alternative pathway. In addition, although all cell lines express CFD mRNA, CFD protein, a co-factor of CFB that activates the alternative pathway, was only reliably detected in neuron and astrocyte supernatants. We also observed that all ASD and control cell lines analyzed express CFH and CFI mRNA and secrete relatively high levels of CFH and CFI proteins, which are inhibitors of the classic and alternative pathways of the complement system. Whereas the expression of these complement components and regulators are implicated in cerebral inflammation [38], degeneration [39] and retinopathies [40, 41], the physiological roles of these proteins in the developing human nervous system deserve further investigation.

Finally, we observed constitutive expression and secretion of the critical component of both classical and lectin cascades C4 by ASD and control NPCs, neurons and astrocytes, and also constitutive secretion of C4b by ASD and control neurons and astrocytes. Interestingly, we found that astrocytes derived from individuals with ASD express significantly lower levels of C4A/B mRNA and secret significantly lower levels of C4 protein compared to control astrocytes. In the brain, C4 localizes to synapses and, together with other members of the classic complement cascade, has been shown to be required for synaptic elimination by microglia in the mouse developing visual system, as mice deficient for complement C1q, C3, CR3 or C4 exhibit impaired elimination of retinogeniculate synapses [6–8]. Accordingly, over-expression of C4 in the mouse prefrontal cortex caused alterations in dendritic spine development, reduced connectivity, increased synaptic pruning, and deficits in social behavior [9].

In humans, C4 is encoded by two different genes, C4A and C4B, which are located in tandem on the short arm of chromosome 6 and vary in copy number [8]. Whereas C4B null alleles that decrease the expression of C4 have been associated with ASD [16–18], alleles at C4A that increase the expression of C4 have been associated with schizophrenia and, mechanistically, it has been proposed that augmented C4 is involved in the exacerbated synaptic pruning and decreased synapse number in schizophrenic patients [8]. Therefore, taking all the above mentioned data into account and the fact that astrocytes regulate synapse formation, elimination and activity [42–44], it is tempting to speculate that a reduced secretion of astrocyte-derived C4 might contribute to the reduced synaptic pruning and increased dendritic spine density in the brain of individuals with ASD [45, 46]. However, additional studies are clearly needed to determine the consequences of decreased astrocyte-derived C4 in brain development and in ASD pathophysiology, and also to explore the C4 locus structure in ASD individuals.

In summary, our results provide insights into the expression patterns of a broad range complement genes and proteins in iPSC-derived NPCs, neurons and astrocytes, and revealed decreased expression and secretion of complement C4 by astrocytes derived from ASD individuals. Also, our findings highlight the use of human iPSC-derived neuronal and glial cells as effective platforms for the study of the complement system in human neurodevelopment.

Declarations
Acknowledgements

We are grateful to all the subjects who participated in this work and their family members. We thank Rafaelly Mayara Dantas Carlos, Bruno Yukio Yokota, and Isabella de Sousa Nóbrega for technical assistance.

Funding

This work was supported by grants from Sao Paulo Research Foundation (FAPESP) [grant number 2015/50138-4] and National Council for Scientific and Technological Development (CNPq).

Conflicts of interest/Competing interests

The authors declare no competing interests.

Availability of data and material

All raw data are available from the corresponding author on reasonable request.

Code availability

Not applicable.

Authors’ contributions

FM, ALTS, AKSG, JM, and JSS conducted the experiments and contributed to the acquisition, analysis, and interpretation of the data. FM wrote the first draft of the manuscript with input from all authors. KGO and MRPB critically reviewed the manuscript. ALS conceived the project, handled the funding, supervised the results, and edited the manuscript.

Ethics approval

This study was approved by the Ethics Committees of the Instituto de Biociências, Universidade de São Paulo, and of the Hospital Israelita Albert Einstein.

Consent to participate

Written informed consent was obtained from all subjects’ caregivers after receiving information about the study.

Consent for publication

Not applicable.

Declaration of interests
The authors declare no competing interests.

References

1. Bajic G, Degn SE, Thiel S, Andersen GR (2015) Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 12;34(22):2735-57. doi: 10.15252/embj.201591881
2. Veerhuis R, Nielsen HM, Tenner AJ (2011) Complement in the brain. Mol Immunol 48(14):1592–1603. doi:10.1016/j.molimm.2011.04.003
3. Coulthard LG, Hawksworth OA, Woodruff TM (2018) Complement: The Emerging Architect of the Developing Brain. Trends Neurosci 41(6):373–384. doi:10.1016/j.tins.2018.03.009
4. Coulthard LG, Hawksworth OA, Conroy J, Lee JD, Woodru TM (2018a) Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance. Mol Immunol 101:176–181. doi:10.1016/j.molimm.2018.06.271
5. Gorelik A, Sapir T, Haffner-Krausz R, Olender T, Woodruff TM, Reiner O (2017) Developmental activities of the complement pathway in migrating neurons. Nat Commun 2:8:15096. doi:10.1038/ncomms15096
6. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA (2007) The classical complement cascade mediates CNS synapse elimination. Cell. 14;131(6):1164-78. doi: 10.1016/j.cell.2007.10.036
7. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B (2012) Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 24(4):691–705. doi:10.1016/j.neuron.2012.03.026. 74
8. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Daly MJ, Carroll MC, Stevens B, McCarroll SA (2016) Schizophrenia risk from complex variation of complement component 4. Nature. 1;530(7589):177 – 83. doi: 10.1038/nature16549
9. Comer AL, Jinadasa T, Sriram B, Phadke RA, Kretsge LN, Nguyen TPH, Antognetti G, Gilbert JP, Lee J, Newmark ER, Hausmann FS, Rosenthal S, Liu Kot K, Liu Y, Yen WW, Dejanovic B, Cruz-Martín A (2020) Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. PLoS Biol. 14;18(1):e3000604. doi: 10.1371/journal.pbio.3000604
10. Magdalon J, Mansur F, Teles E, Silva AL, de Goes VA, Reiner O, Sertié AL (2020) Complement System in Brain Architecture and Neurodevelopmental Disorders. Front Neurosci Feb 5:14:23. doi:10.3389/fnins.2020.00023
11. Nardone S, Sams DS, Reuveni E, Getselter D, Oron O, Karpuj M, Elliott E (2014) DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways. Transl Psychiatry. Sep 2;4(9):e433. doi: 10.1038/tp.2014.70
12. Fagan K, Crider A, Ahmed AO, Pillai A (2017) Complement C3 Expression Is Decreased in Autism Spectrum Disorder Subjects and Contributes to Behavioral Deficits in Rodents. Mol Neuropsychiatry 3(1):19–27. doi:10.1159/000465523
13. APA (2013) Diagnostic and Statistical Manual of Mental Disorders. 5th Edn. Washington, DC: American Psychiatric Association
14. Bourgeron T (2015) From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat Rev Neurosci 16(9):551–563. doi:10.1038/nrn3992
15. Estes ML, McAllister AK (2015) Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci 16(8):469–486. doi:10.1038/nrn3978
16. Warren RP, Singh VK, Cole P, Odell JD, Pingree CB, Warren WL, White E (1991) Increased frequency of the null allele at the complement C4b locus in autism. Clin Exp Immunol 83(3):438–440. doi:10.1111/j.1365-2249.1991.tb05657.x
17. Odell D, Maciulis A, Cutler A, Warren L, McMahon WM, Coon H, Stubbs G, Henley K, Torres A (2005) Confirmation of the association of the C4B null allele in autism. Hum Immunol 66(2):140–145. doi:10.1016/j.humimm.2004.11.002
18. Mostafa GA, Shehab AA (2010) The link of C4B null allele to autism and to a family history of autoimmunity in Egyptian autistic children. J Neuroimmunol 223(1–2):115–119. doi:10.1016/j.jneuroim.2010.03.025
19. Warren RP, Burger RA, Odell D, Torres AR, Warren WL (1994) Decreased plasma concentrations of the C4B complement protein in autism. Arch Pediatr Adolesc Med 148(2):180–183. doi:10.1001/archpedi.1994.02170020066011
20. Corbett BA, Kantor AB, Schulman H, Walker WL, Lit L, Ashwood P, Rocke DM, Sharp FR (2007) A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry 12(3):292–306. doi:10.1038/sj.mp.4001943
21. Shen L, Zhang K, Feng C, Chen Y, Li S, Iqbal J, Liao L, Zhao Y, Zhai J (2018) iTRAQ-Based Proteomic Analysis Reveals Protein Profile in Plasma from Children with Autism. Proteomics Clin Appl 12(3):e1700085. doi:10.1002/prca.201700085
22. Momeni N, Brudin L, Behnia F, Nordström B, Yosefi-Oudarji A, Sivberg B, Joghataei MT, Persson BL (2012) High complement factor I activity in the plasma of children with autism spectrum disorders. Autism Res Treat 2012:868576. doi:10.1155/2012/868576
23. Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L, Amenduni M, Szekely A, Palejev D, Wilson M, Gerstein M, Grigorenko EL, Chawarska K, Pelphrey KA, Howe JR, Vaccarino FM (2015) FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. Cell. 16;162(2):375–390. doi: 10.1016/j.cell.2015.06.034
24. Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria K, Beltrao-Braga P, Trujillo CA, Mendes APD, Padmanabhan K, Nunez Y, Ou J, Ghosh H, Wright R, Brennand K, Pierce K, Eichenfield L, Pramparo T, Eyler L, Barnes CC, Courchesne E, Geschwind DH, Gage FH, Wynshaw-Boris A, Muotri AR (2017) Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. Mol Psychiatry 22(6):820–835. doi:10.1038/mp.2016.95

25. Russo FB, Freitas BC, Pignatari GC, Fernandes IR, Sebat J, Muotri AR, Beltrão-Braga PCB (2018) Modeling the Interplay Between Neurons and Astrocytes in Autism Using Human Induced Pluripotent Stem Cells. Biol Psychiatry. 1;83(7):569–578. doi: 10.1016/j.biopsych.2017.09.021

26. Schafer ST, Paquola ACM, Stem S, Gosselin D, Ku M, Pena M, Kuret TJM, Liyanage M, Mansour AA, Jaeger BN, Marchetto MC, Glass CK, Mertens J, Gage FH (2019) Pathological priming causes developmental gene network heterochronicity in autistic subject-derived neurons. Nat Neurosci 22(2):243–255. doi:10.1038/s41593-018-0295-x

27. Griesi-Oliveira K, Fogo MS, Pinto BGG, Alves Ay, Suzuki AM, Morales AG, Ezquina S, Sosa OJ, Sutton GJ, Sunaga-Franze DY, Bueno AP, Seabra G, Sardinha L, Costa SS, Rosenberg C, Zachi EC, Sertié AL, Martins-de-Souza D, Reis EM, Voineagu I, Passos-Bueno MR (2020) Transcriptome of iPSC-derived neuronal cells reveals a module of co-expressed genes consistently associated with autism spectrum disorder. Mol Psychiatry. 14. doi: 10.1038/s41380-020-0669-9

28. Suzuki AM, Griesi-Oliveira K, de Oliveira Freitas Machado C, Vadasz E, Zachi EC, Passos-Bueno MR, Sertié AL (2015) Altered mTORC1 signaling in multipotent stem cells from nearly 25% of patients with nonsyndromic autism spectrum disorders. Mol Psychiatry 20(5):551–552. doi:10.1038/mp.2014.175

29. Sánchez-Sánchez SM, Magdalon J, Griesi-Oliveira K, Yamamoto GL, Santacruz-Perez C, Fogo M, Passos-Bueno MR, Sertié AL (2018) Rare RELN variants affect Reelin-DAB1 signal transduction in autism spectrum disorder. Hum Mutat Oct 39(10):1372–1383. doi:10.1002/humu.23584

30. da Silva Montenegro EM, Costa CS, Campos G, Sciliar M, de Almeida TF, Zachi EC, Silva IMW, Chan AJS, Zarrei M, Lourenço NCV, Yamamoto GL, Scherer S, Passos-Bueno MR (2020) Meta-Analyses Support Previous and Novel Autism Candidate Genes: Outcomes of an Unexplored Brazilian Cohort. Autism Res 13(2):199–206. doi:10.1002/aur.2238

31. Araujo BHS, Kaid C, De Souza JS, Gomes da Silva S, Goulart E, Caires LCJ, Musso CM, Torres LB, Ferrasa A, Herai R, Zatz M, Okamoto OK, Cavalheiro EA (2018) Down Syndrome iPSC-Derived Astrocytes Impair Neuronal Synaptogenesis and the mTOR Pathway In Vitro. Mol Neurobiol 55(7):5962–5975. doi:10.1007/s12035-017-0818-6

32. Denny KJ, Coulthard LG, Jeannes A, Lisgo S, Simmons DG, Callaway LK, Wlodarczyk B, Finnell RH, Woodruff TM, Taylor SM (2013) C5a receptor signaling prevents folate deficiency-induced neural tube defects in mice. J Immunol. 1;190(7):3493-9. doi: 10.4049/jimmunol.1203072

33. Hawksworth OA, Coulthard LG, Taylor SM, Wolvetang EJ, Woodruff TM (2014) Brief report: complement C5a promotes human embryonic stem cell pluripotency in the absence of FGF2. Stem Cells Dec;32(12):3278–3284. doi:10.1002/stem.1801
34. Coulthard LG, Hawksworth OA, Li R, Balachandran A, Lee JD, Sepehrband F, Kurniawan N, Jeanes A, Simmons DG, Wolvetang E, Woodruff TM (2017) Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCζ. J Neurosci. 31;37(22):5395–5407. doi: 10.1523/JNEUROSCI.0525-17.2017

35. Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Götze O, Morgan BP (1995) Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol. 15;155(10):4882-9

36. Pavlovski D, Thundyil J, Monk PN, Wetsel RA, Taylor SM, Woodruff TM (2012) Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J 26(9):3680–3690. doi:10.1096/fj.11-202382

37. Hernandez MX, Namiranian P, Nguyen E, Fonseca MI, Tenner AJ (2017) C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta. ASN Neuro 9(1):1759091416687871. doi:10.1177/1759091416687871

38. Altmann T, Torvell M, Owens S, Mitra D, Sheerin NS, Morgan BP, Kavanagh D, Forsyth R (2020) Complement factor I deficiency: A potentially treatable cause of fulminant cerebral inflammation. Neurol Neuroimmunol Neuroinflamm. 25;7(3):e689. doi: 10.1212/NXI.0000000000000689

39. Zhang DF, Li J, Wu H, Cui Y, Bi R, Zhou HJ, Wang HZ, Zhang C, Wang D; Alzheimer's Disease Neuroimaging Initiative (ADNI), Kong QP, Li T, Fang Y, Jiang T, Yao YG (2016) CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer's Disease. Neuropsychopharmacology. 41(4):1034-45. doi: 10.1038/npp.2015.232

40. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29(2):95–112. doi:10.1016/j.preteyeres.2009.11.003

41. Chrzanska M, Modrzejewska A, Modrzejewska M (2018) New insight into the role of the complement in the most common types of retinopathy-current literature review. Int J Ophthalmol 11(11):1856–1864. doi:10.18240/ijo.2018.11.19

42. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, Smith SJ, Barres BA (2013) Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 19;504(7480):394–400. doi: 10.1038/nature12776

43. Clarke LE, Barres BA (2013) Emerging roles of astrocytes in neural circuit development. Nat Rev Neurosci 14(5):311–321. doi:10.1038/nrn3484

44. Araque A, Carmignoto G, Haydon PG, Oliet SH, Robitaille R, Volterra A (2014) Gliotransmitters travel in time and space. Neuron. 19;81(4):728 – 39. doi: 10.1016/j.neuron.2014.02.007

45. Hutsler JJ, Zhang H (2010) Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res 14:1309:83–94. doi:10.1016/j.brainres.2009.09.120

46. Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A, Sonders MS, Kanter E, Castagna C, Yamamoto A, Yue Z, Arancio O, Peterson BS, Champagne F, Dwork AJ, Goldman J, Sulzer D (2014)
Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron. 3;83(5):1131-43. doi: 10.1016/j.neuron.2014.07.040